Posaconazole therapeutic drug monitoring: a reference laboratory experience.
作者信息
Thompson George R, Rinaldi Michael G, Pennick Gennethel, Dorsey Sheryl A, Patterson Thomas F, Lewis James S
出版信息
Antimicrob Agents Chemother. 2009 May;53(5):2223-4. doi: 10.1128/AAC.00240-09. Epub 2009 Mar 2.
Abstract
摘要
相似文献
1
Posaconazole therapeutic drug monitoring: a reference laboratory experience.泊沙康唑治疗药物监测：参考实验室经验
Antimicrob Agents Chemother. 2009 May;53(5):2223-4. doi: 10.1128/AAC.00240-09. Epub 2009 Mar 2.
2
HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases.血液系统疾病患者中抗真菌药物泊沙康唑的高效液相色谱分析。
Mycoses. 2006;49 Suppl 1:17-22. doi: 10.1111/j.1439-0507.2006.01297.x.
3
Posaconazole: the case for therapeutic drug monitoring.泊沙康唑：治疗药物监测的案例。
Ther Drug Monit. 2012 Feb;34(1):72-6. doi: 10.1097/FTD.0b013e31823cdeac.
4
Long-term treatment of refractory invasive fungal infection with posaconazole: additive value of therapeutic drug monitoring.
Acta Clin Belg. 2011 May-Jun;66(3):231-2. doi: 10.2143/ACB.66.3.2062555.
5
Posaconazole serum level on day 2 predicts steady state posaconazole serum level.第2天的泊沙康唑血清水平可预测泊沙康唑血清稳态水平。
Ther Drug Monit. 2012 Feb;34(1):118-9. doi: 10.1097/FTD.0b013e31823cef77.
6
What should be the first-choice strategy to maximize posaconazole exposure in daily clinical practice?在日常临床实践中，使泊沙康唑暴露量最大化的首选策略应该是什么？
Antimicrob Agents Chemother. 2009 Aug;53(8):3608-9; author reply 609-10. doi: 10.1128/AAC.00256-09.
7
Plasma exposures following posaconazole delayed-release tablets in immunocompromised children and adolescents.免疫功能低下的儿童和青少年服用泊沙康唑延迟释放片后的血浆暴露情况。
J Antimicrob Chemother. 2019 Dec 1;74(12):3573-3578. doi: 10.1093/jac/dkz359.
8
A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis.中性粒细胞减少症血液病患者接受泊沙康唑预防治疗时泊沙康唑血药浓度的上市后评估。
Int J Antimicrob Agents. 2011 Mar;37(3):266-9. doi: 10.1016/j.ijantimicag.2010.11.021. Epub 2011 Jan 13.
9
Relevance of timing for determination of posaconazole plasma concentrations.泊沙康唑血药浓度监测时间的相关性。
Antimicrob Agents Chemother. 2011 Jul;55(7):3621-3. doi: 10.1128/AAC.00062-11. Epub 2011 Apr 18.
10
Plasma concentrations of posaconazole administered via nasogastric tube in patients in a surgical intensive care unit.重症加强护理病房患者经鼻胃管给予泊沙康唑的血浆浓度。
Antimicrob Agents Chemother. 2012 Aug;56(8):4468-70. doi: 10.1128/AAC.06167-11. Epub 2012 May 14.
引用本文的文献
1
MSG-15: Super-Bioavailability Itraconazole Versus Conventional Itraconazole in the Treatment of Endemic Mycoses-A Multicenter, Open-Label, Randomized Comparative Trial.MSG - 15：超生物利用度伊曲康唑与传统伊曲康唑治疗地方性真菌病的多中心、开放标签、随机对照试验
Open Forum Infect Dis. 2024 Jan 29;11(3):ofae010. doi: 10.1093/ofid/ofae010. eCollection 2024 Mar.
2
Piperazine based antimicrobial polymers: a review.基于哌嗪的抗菌聚合物：综述
RSC Adv. 2021 Apr 23;11(25):15213-15230. doi: 10.1039/d1ra00341k. eCollection 2021 Apr 21.
3
Comparative study of prophylaxis with high and low doses of voriconazole in children with malignancy.高剂量与低剂量伏立康唑对恶性肿瘤患儿预防作用的对比研究
Curr Med Mycol. 2020 Dec;6(4):27-34. doi: 10.18502/cmm.6.4.5331.
4
The Rise of : Forces Against the Dust Devil Unleashed.《尘卷风的崛起：反抗势力的释放》。
Front Immunol. 2019 Sep 11;10:2188. doi: 10.3389/fimmu.2019.02188. eCollection 2019.
5
Impact of Triazole Therapeutic Drug Monitoring Availability and Timing.三唑类治疗药物监测的可及性和时间对其的影响。
Antimicrob Agents Chemother. 2019 Sep 23;63(10). doi: 10.1128/AAC.01245-19. Print 2019 Oct.
6
Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials.真实世界实践中的伊曲康唑浓度：与临床试验结果的一致性。
Antimicrob Agents Chemother. 2018 Jun 26;62(7). doi: 10.1128/AAC.00585-18. Print 2018 Jul.
7
Prevention of Invasive Aspergillus Fungal Infections with the Suspension and Delayed-Release Tablet Formulations of Posaconazole in Patients with Haematologic Malignancies.泊沙康唑混悬剂和延迟释放片治疗血液恶性肿瘤患者侵袭性曲霉菌感染的预防。
Sci Rep. 2018 Jan 26;8(1):1681. doi: 10.1038/s41598-018-20136-3.
8
Comparing Azole Plasma Trough Levels in Lung Transplant Recipients: Percentage of Therapeutic Levels and Intrapatient Variability.比较肺移植受者中的唑类药物血浆谷浓度：治疗水平百分比和患者内变异性
Ther Drug Monit. 2017 Apr;39(2):93-101. doi: 10.1097/FTD.0000000000000371.
9
Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infections.泊沙康唑缓释片用于侵袭性真菌感染的药代动力学及安全性
Clin Pharmacol. 2015 Dec 23;8:1-8. doi: 10.2147/CPAA.S60933. eCollection 2016.
10
Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia.泊沙康唑对急性髓系白血病患者进行预防治疗的药代动力学
J Infect Chemother. 2015 Sep;21(9):663-7. doi: 10.1016/j.jiac.2015.05.011. Epub 2015 Jun 9.
本文引用的文献
1
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.健康志愿者在不同胃部条件下泊沙康唑口服混悬液的药代动力学及吸收情况。
Antimicrob Agents Chemother. 2009 Mar;53(3):958-66. doi: 10.1128/AAC.01034-08. Epub 2008 Dec 15.
2
Antifungal therapeutic drug monitoring: established and emerging indications.抗真菌治疗药物监测：既定及新出现的适应证
Antimicrob Agents Chemother. 2009 Jan;53(1):24-34. doi: 10.1128/AAC.00705-08. Epub 2008 Oct 27.
3
Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease.口服泊沙康唑在患有移植物抗宿主病的异基因造血干细胞移植受者中的药代动力学。
Pharmacotherapy. 2007 Dec;27(12):1627-36. doi: 10.1592/phco.27.12.1627.
4
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.泊沙康唑与氟康唑或伊曲康唑对中性粒细胞减少患者的预防作用比较
N Engl J Med. 2007 Jan 25;356(4):348-59. doi: 10.1056/NEJMoa061094.
5
Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.泊沙康唑或氟康唑用于严重移植物抗宿主病的预防。
N Engl J Med. 2007 Jan 25;356(4):335-47. doi: 10.1056/NEJMoa061098.
6
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.泊沙康唑治疗对传统疗法难治或不耐受的侵袭性曲霉病患者：一项外部对照试验。
Clin Infect Dis. 2007 Jan 1;44(1):2-12. doi: 10.1086/508774. Epub 2006 Nov 28.
7
Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients.口服泊沙康唑在中性粒细胞减少的干细胞移植受者中的药代动力学及安全性
Antimicrob Agents Chemother. 2006 Jun;50(6):1993-9. doi: 10.1128/AAC.00157-06.
8
Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection.泊沙康唑在持续性发热性中性粒细胞减少症或难治性侵袭性真菌感染患者中的药代动力学、安全性及疗效
Antimicrob Agents Chemother. 2006 Feb;50(2):658-66. doi: 10.1128/AAC.50.2.658-666.2006.
Zotero 插件